Recombinant erythropoietin is being used in premature population for anemia of prematurity. It is considered very safe in this population, although risks are still being evaluated. We report the first case of dermal erythropoiesis as a side effect of recombinant erythropoietin in an extremely prematurely born infant presenting with late-onset blueberry muffin lesions.
Departments of *Pediatrics, Division of Neonatology
‡Pathology, University of Kansas, School of Medicine
†Neonatal Intensive Care Unit
§Department of Pathology and Laboratory Medicine, University of Kansas Hospital, Kansas City, KS
The authors declare no conflict of interest.
Reprints: Vishal Pandey, MD, 3901 Rainbow Blvd, Wescoe 3037A, Mail Stop: 2030, Kansas City, KS 66160 (e-mail: email@example.com).
Received September 20, 2011
Accepted June 26, 2012